Solenic Medical

What Solenic Medical does

Solenic Medical, Inc. is a privately held, pre-revenue medical device company founded in June 2019 as a portfolio company of VIC Technology Venture Development to commercialize alternating magnetic field (AMF) technology exclusively licensed from UT Southwestern Medical Center. The company is headquartered in Addison, Texas and operates with 11–50 employees, focused on a single clinical indication: prosthetic joint infection (PJI) of metallic orthopedic implants, where infection is the leading cause of knee revision surgery (33.1% of total knee revisions 2012–2023) and the most common reason for hip revision (21.4%) per the AJRR 2024 annual report.

The company's core product is the SOLA-2 AMF Knee System, a non-invasive, non-contact therapeutic device that delivers a controlled alternating magnetic field to the metallic components of compatible knee implants. The AMF generates a selective thermal dose within approximately 1 mm of the implant surface, eradicating biofilm and bacteria while preserving surrounding tissue and acting synergistically with systemic antibiotics. The first-generation device is designed for use in an operating room setting on subjects with confirmed or suspected periprosthetic joint infection. Solenic's competitive positioning is anchored in FDA Breakthrough Device Designation (July 2020), 13+ peer-reviewed publications, GLP animal study results, and an Investigational Device Exemption pathway that has progressed from Early Feasibility approval (August 2024) to first-patient treatment (April 2025), compassionate-use authorization (October 2025), and pivotal trial IDE approval (June 2026).

Solenic's business model is hardware sales of the SOLA-2 device to hospitals and orthopedic surgery centers upon FDA approval, distributed via a direct enterprise field-sales motion targeting orthopedic surgeons. The company is currently pre-commercial with no product revenue; near-term monetization is contingent on PMA approval following the pivotal trial. Capitalization is approximately $12.7 million across venture (VIC seed, Johnson & Johnson Innovation – JJDC-led $5.1M Series A in June 2023, a ~$5.4M round in February 2024), non-dilutive (NIH $1.3M), and accelerator sources. The leadership team blends scientific founders (CMO Dr. David Greenberg and CTO Dr. Rajiv Chopra, the original co-inventors) with commercial operators (CEO Bart Bandy, ex-J&J/Allergan; VP Strategic Marketing Jose Guzman, ex-DePuy/Zimmer Biomet), positioning the company for the transition from clinical development to commercial launch.

Name

Solenic Medical

Legal name

Solenic Medical, Inc.

Website

https://solenic.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Solenic Medical is a pre-revenue medical device company developing the SOLA-2 AMF System, a non-invasive, non-contact device that uses alternating magnetic fields to eradicate biofilm on metallic knee implants and treat prosthetic joint infections as an alternative to revision surgery.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

akta.pro secondary industry

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Non-invasive implant treatment
• Alternating magnetic field therapy
• Biofilm eradication devices
• Prosthetic joint infection treatment
• Orthopedic medical devices

Headquarters

HQ city

College Station

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (Pre-commercial): Solenic Medical is a pre-revenue medical device company developing the SOLA2 AMF Knee System. The company is currently in clinical trial phase (Early Feasibility and Pivotal IDE trials). No commercial revenue has been generated as of the latest data. Revenue will be generated through device sales to hospitals and orthopedic surgery centers upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Solenic Medical is developing the SOLA-2™ AMF System, a first-generation non-invasive, non-contact medical device that uses patented Alternating Magnetic Field (AMF) technology to deliver controlled thermal energy to metallic knee implant surfaces, eradicating biofilm and bacteria in patients with periprosthetic joint infections (PJI). The company is pre-commercial and currently conducting FDA-approved Early Feasibility and Pivotal IDE clinical trials, with future revenue expected from device sales to hospitals and orthopedic surgery centers.

Product overview

Solenic Medical offers a non-invasive platform technology using patented alternating magnetic fields (AMF) to treat infected metallic implants. The primary product is the SOLA-2™ AMF System (also called the Sola2 AMF Knee System), which delivers controlled thermal treatment to metallic knee implant surfaces to eradicate biofilm and bacteria. The platform technology enables non-invasive treatment of prosthetic joint infections, potentially replacing the need for risky and expensive revision surgeries.

Differentiator

Problem solved

Functional benefit

Brands

• SOLA-2: First-generation AMF Knee System - a non-invasive, non-contact device designed to deliver an alternating magnetic field to metallic components of compatible knee implants, targeting biofilm in subjects with confirmed or suspected periprosthetic joint infection.

Products and services

• SOLA-2™ AMF System Non-invasive, non-contact device that delivers alternating magnetic fields to metallic knee implant components, targeting biofilm in subjects with confirmed or suspected periprosthetic joint infection (PJI) in an operating room setting.
• Sola2 AMF Knee System First-generation AMF device specifically designed for knee implants, delivering controlled thermal treatment via alternating magnetic fields to eradicate biofilm and bacteria on metallic implant surfaces.
• AMF Technology Platform Non-invasive platform technology using patented alternating magnetic field (AMF) technology to eradicate biofilms on metallic implant surfaces, targeting prosthetic joint infections as an alternative to revision surgery.

Quantifiable outcome

• Current two-stage revision surgery has failure rate up to 18% and reinfection rate estimated at 8.8%
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• University of Texas Southwestern Medical Center (UTSW)coreStrategic or Co-development PartnerTechnology exclusively licensed from UTSW for treating prosthetic joint infections using alternating magnetic fields. The Greenberg and Chopra laboratories at UTSW discovered the novel AMF method for treating PJIs. Solenic Medical was formed in June 2019 specifically to develop and commercialize this UTSW-licensed technology.
• JLABS @ TMC (Johnson & Johnson Innovation)minorStrategic or Co-development PartnerSolenic Medical was selected as an award recipient in the JLABS @ TMC Breakthrough Medical Technologies QuickFire Challenge in November 2019. The challenge was designed to ignite innovation in health tech and provide resources to advance science.
• MedTech InnovatorminorStrategic or Co-development PartnerSolenic Medical was selected to participate in the MedTech Innovator 2024 Accelerator Cohort after a competitive selection process with a five percent acceptance rate. The program is the world's largest accelerator of medical technology companies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Smith+Nephew: Global orthopedic medical device incumbent with knee and hip implant portfolios plus established PJI revision surgery product lines. Relevant as the entrenched competitor whose revision franchise Solenic aims to disrupt non-invasively.
• Zimmer Biomet: One of the largest orthopedic device companies globally, with dominant knee and hip implant franchises and revision surgery systems. Relevant as the dominant incumbent whose two-stage revision workflow Solenic is positioning to replace.
• DePuy Synthes (Johnson & Johnson): J&J's orthopedic and trauma implant franchise, including knee, hip, and revision products. Strategic dual role: incumbent competitor to Solenic and strategic investor (JJDC led the Series A), making it both a commercialization risk and a potential exit path.

Direct peers

• Microbion Corporation: Clinical-stage biotech developing antibiofilm therapeutics (e.g., MBN-101) for chronic and implant-associated infections. Directly comparable to Solenic in targeting biofilm-driven infections on medical devices, though it uses small-molecule therapeutics rather than energy-based delivery.
• N8 Medical: Develops antimicrobial and antibiofilm coatings for medical implants, including orthopedic and dental applications. Comparable because both companies target prevention and treatment of biofilm on implanted hardware, although N8's approach is coating-based rather than energy-based.
• Kane Biotech: Canadian biotech commercializing biofilm-disrupting enzyme and antimicrobial products for wound care, dental implants, and veterinary applications. Direct peer in the biofilm-targeting therapeutic space with adjacent orthopedic/dental implant indications.

Emerging players

• Destiny Pharma: UK-listed clinical-stage company developing the XF platform of antimicrobial drugs targeting drug-resistant bacteria and biofilms, including prevention of post-surgical infections. Comparable in therapeutic approach to biofilm-associated infections but uses topical drug delivery rather than electromagnetic energy.
• Citius Pharmaceuticals: Late-stage specialty pharma with Mino-Lok, an antibiotic lock therapy for catheter-related bloodstream infections and biofilm eradication. Comparable in the antimicrobial biofilm-treatment category, though focused on catheter rather than orthopedic implant indications.
• Armata Pharmaceuticals: Clinical-stage developer of bacteriophage therapeutics for antibiotic-resistant bacterial infections, including Staphylococcus aureus biofilm targets relevant to PJI. Overlaps with Solenic's anti-biofilm strategy but uses phage rather than electromagnetic delivery.

Others

• Mölnlycke Health Care: Global wound care and infection-prevention company (Mepilex, Avance negative pressure wound therapy) used in surgical and PJI post-operative management. Indirectly comparable as a stakeholder in the PJI care pathway that Solenic could displace or complement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights8 records

Customer concentration

• Xx.com/SolenicMedical
• LinkedInlinkedin.com/company/solenic-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solenic Medical